Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Jimenez-Ubieto, AnaPaiva, BrunoPuig, NoemiCedena, Maria-TeresaMartinez-Lopez, JoaquinOriol, AlbertBlanchard, Maria-JesusRios, RafaelMartin, JesusMartinez, RafaelSureda, AnnaHernandez, Miguel-Teodorode la Rubia, JavierKrnisk, IsabelCabanas, ValentinPalomera, LuisSanchez-Pina, Jose MariaBargay, JoanMateos, Maria-VictoriaRosinol, LauraBlade, JoanSan Miguel, JesusLahuerta, Juan JoseGEM Grp Espanol MielomaPETHEMA Programa Espanol Tratam2025-01-072025-01-072021-11-110006-4971https://hdl.handle.net/10668/26424enMinimal residual diseaseMultiple-myelomaTransplantationBortezomibTherapyValidation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?research article34329372open access10.1182/blood.20210123191528-0020https://ashpublications.org/blood/article-pdf/138/19/1901/1834685/bloodbld2021012319.pdf719912100014